

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 – 42. Cancelled.

43. (Currently Amended) A pharmaceutical formulation for oral administration of insulin comprising a particulate pharmaceutical substrate having an application of an insulin coating, wherein the particulate pharmaceutical substrate exclusively is dibasic calcium phosphate dehydrate having a diameter less than about 420 microns.

44. (Previously amended) The oral pharmaceutical formulation of claim 43, wherein the insulin coating includes an agent selected from the group consisting of coating agents, controlled release agents, sustained release agents, pharmaceutical excipient agents, and combinations thereof.

45. (Original) The oral pharmaceutical formulation of claim 44, wherein the agent is selected from the group consisting of colorants, film-forming polymers, plasticizers, surfactants, permeation enhancers, buffering agents, dispersions of ethyl cellulose, coating lacquers, pigments, and combinations thereof.

46. (Original) The oral pharmaceutical formulation of claim 43, wherein the insulin comprises an insulin load on the substrate ranging from about 0.1% to about 30% weight/weight.

Claims 47-48. (Cancelled)

49. (Original) The oral pharmaceutical formulation of claim 43, further including another coating.

50. (Original) The oral pharmaceutical formulation of claim 49, wherein another coating is under the insulin coating, over the insulin coating, or a combination thereof.

51. (Previously amended) The oral pharmaceutical formulation of claim 43, wherein the other coating comprises an agent selected from the group consisting of coating agents, controlled release agents, sustained release agents, pharmaceutical excipient agents, and combinations thereof.

52. (Original) The oral pharmaceutical formulation of claim 51, wherein the agent is selected from the group consisting of colorants, film-forming polymers, plasticizers, surfactants, permeation enhancers, buffering agents, dispersions of ethyl cellulose, coating lacquers, pigments, and combinations thereof.

53. (Original) The oral pharmaceutical formulation of claim 43, wherein the particulate pharmaceutical substrate having an application of an insulin coating is encapsulated in a gelatin capsule or is compressed into a tablet.

Claim 54 (Cancelled).

55. (Currently amended) An oral pharmaceutical formulation of insulin comprising a particulate dibasic calcium phosphate dihydrate pharmaceutical substrate free of other components, each particle having a diameter less than about 420 microns, and having an application of an insulin coating, wherein: (a) the insulin is present in a load on the substrate ranging from about 0.1% to 30% weight/weight, and (b) the substrate is coated with a permeation enhancer.

56. (Previously Presented) The oral pharmaceutical formulation of Claim 43, wherein the insulin is hexyl insulin monoconjugate-2 polydisperse.

57. (Previously Presented) The oral pharmaceutical formulation of Claim 55, wherein the insulin is hexyl insulin monoconjugate-2 polydisperse.

Claims 58 – 68. Cancelled.